• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Nkarta Inc. (Amendment)

    2/9/24 6:38:26 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NKTX alert in real time by email
    SC 13D/A 1 d597814dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Nkarta, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

    65487U108

    (CUSIP Number)

    Bas Vaessen

    LSP 6 Management B.V.

    Johannes Vermeerplein 9

    Amsterdam, Netherlands, 1071 DV

    +31 20 664 5500

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    February 8, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☒

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


     1   

     Names of Reporting Persons

     

     LSP 6 Management B.V.

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Source of Funds (See Instructions)

     

     OO

     5  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     ☐

     6  

     Citizenship or Place of Organization

     

     Netherlands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     Sole Voting Power

     

     0

        8  

     Shared Voting Power

     

     2,836,539

        9  

     Sole Dispositive Power

     

     0

       10  

     Shared Dispositive Power

     

     2,836,539

    11   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     2,836,539

    12  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

     ☐

    13  

     Percent of Class Represented by Amount in Row (11)

     

     5.8%

    14  

     Type of Reporting Person

     

     OO


     1   

     Names of Reporting Persons

     

     LSP 6 Holding C.V.

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Source of Funds (See Instructions)

     

     OO

     5  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     ☐

     6  

     Citizenship or Place of Organization

     

     United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     Sole Voting Power

     

     0

        8  

     Shared Voting Power

     

     1,419,873

        9  

     Sole Dispositive Power

     

     0

       10  

     Shared Dispositive Power

     

     1,419,873

    11   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,419,873

    12  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

     ☐

    13  

     Percent of Class Represented by Amount in Row (11)

     

     2.9%

    14  

     Type of Reporting Person

     

     OO

     


     1   

     Names of Reporting Persons

     

     LSP 6 NK Holding B.V.

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Source of Funds (See Instructions)

     

     OO

     5  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     ☐

     6  

     Citizenship or Place of Organization

     

     Netherlands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     Sole Voting Power

     

     0

        8  

     Shared Voting Power

     

     1,416,666

        9  

     Sole Dispositive Power

     

     0

       10  

     Shared Dispositive Power

     

     1,416,666

    11   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,416,666

    12  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

     ☐

    13  

     Percent of Class Represented by Amount in Row (11)

     

     2.9%

    14  

     Type of Reporting Person

     

     OO


    Explanatory Note

    This Amendment No. 1 to Schedule 13D (this “Amendment No. 1”) amends and supplements the Statement on Schedule 13D filed with the United States Securities and Exchange Commission on July 24, 2020 (as amended to date, the “Schedule 13D”) relating to the Common Stock, par value par value $0.0001 per share (the “Common Stock”), of Nkarta, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D.

     

    Item 5.

    Interest in Securities of the Issuer.

    (a) – (b)

    The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 49,072,342 shares of the Issuer’s Common Stock outstanding as of November 6, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

     

    Reporting Person

       Amount
    beneficially
    owned
         Percent
    of class
        Sole
    power to
    vote or
    to direct
    the vote
         Shared
    power to
    vote or to
    direct the
    vote
         Sole
    power to
    dispose or
    to direct
    the
    disposition
         Shared
    power to
    dispose or
    to direct
    the
    disposition
     

    LSP 6 Management B.V.

         2,836,539        5.8 %      0        2,836,539        0        2,836,539  

    LSP 6 Holding C.V.

         1,419,873        2.9 %      0        1,419,873        0        1,419,873  

    LSP 6 NK Holding B.V.

         1,416,666        2.9 %      0        1,416,666        0        1,416,666  

    LSP 6 Holding is the record holder of 1,419,873 shares of Common Stock and LSP 6 NK is the record holder of 1,416,666 shares of Common Stock.

    LSP 6 Management is the sole general partner of LSP 6 Holding which is the sole shareholder of LSP 6 NK. The managing directors of LSP 6 Management are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. As such, LSP 6 Management, Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be deemed to beneficially own the shares of Common Stock held of record by LSP 6 Holding and LSP 6 NK.

    Except as set forth in this Item 5(a)-(b), each of the persons named in this Item 5(a)-(b) disclaims beneficial ownership of any shares of Common Stock owned beneficially or of record by any other person named in this Item 5(a)-(b).


    (c)

    Except as described in Item 4, during the past 60 days none of the Reporting Persons has effected any transactions in the Common Stock.

     

    (d)

    None.

     

    (e)

    Not applicable.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 8, 2024

     

    LSP 6 Management B.V.
    By:  

    /s/ René Robert Kuijten

    Name:   René Robert Kuijten
    Title:   Managing Director
    By:  

    /s/ Martijn Kleijwegt

    Name:   Martijn Kleijwegt
    Title:   Managing Director
    LSP 6 Holding C.V.
    By: LSP 6 Management B.V., its general partner
    By:  

    /s/ René Robert Kuijten

    Name:   René Robert Kuijten
    Title:   Managing Director
    By:  

    /s/ Martijn Kleijwegt

    Name:   Martijn Kleijwegt
    Title:   Managing Director
    LSP 6 NK Holding B.V.
    By: LSP 6 Holding C.V., its sole shareholder
    By: LSP 6 Management B.V., its general partner
    By:  

    /s/ René Robert Kuijten

    Name:   René Robert Kuijten
    Title:   Managing Director
    By:  

    /s/ Martijn Kleijwegt

    Name:   Martijn Kleijwegt
    Title:   Managing Director
    Get the next $NKTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NKTX

    DatePrice TargetRatingAnalyst
    5/15/2025Outperform → Mkt Perform
    William Blair
    10/9/2024$14.00Buy
    Rodman & Renshaw
    8/14/2024$16.00Outperform → Strong Buy
    Raymond James
    3/22/2024$13.00 → $16.00Strong Buy → Outperform
    Raymond James
    12/22/2022Outperform → Perform
    Oppenheimer
    10/10/2022$25.00Buy
    Canaccord Genuity
    7/28/2022$26.00Buy
    Needham
    7/18/2022$30.00Outperform
    SVB Leerink
    More analyst ratings

    $NKTX
    SEC Filings

    View All

    SEC Form S-8 filed by Nkarta Inc.

    S-8 - Nkarta, Inc. (0001787400) (Filer)

    1/5/26 4:43:55 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Nkarta Inc.

    SCHEDULE 13D/A - Nkarta, Inc. (0001787400) (Subject)

    11/24/25 6:48:24 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Nkarta Inc.

    SCHEDULE 13G/A - Nkarta, Inc. (0001787400) (Subject)

    11/14/25 4:05:26 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hastings Paul J sold $53,915 worth of shares (26,046 units at $2.07), decreasing direct ownership by 6% to 390,023 units (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    1/20/26 5:39:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Mahmood Nadir sold $11,693 worth of shares (5,649 units at $2.07), decreasing direct ownership by 3% to 167,727 units (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    1/20/26 5:38:03 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Rose Shawn Marshall was granted 70,000 shares (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    1/8/26 5:50:36 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nkarta downgraded by William Blair

    William Blair downgraded Nkarta from Outperform to Mkt Perform

    5/15/25 8:09:11 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Nkarta with a new price target

    Rodman & Renshaw initiated coverage of Nkarta with a rating of Buy and set a new price target of $14.00

    10/9/24 7:55:21 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta upgraded by Raymond James with a new price target

    Raymond James upgraded Nkarta from Outperform to Strong Buy and set a new price target of $16.00

    8/14/24 7:45:34 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nkarta to Participate in Evercore Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8th Annual Healthcare Conference on Thursday in Miami. Evercore 8th Annual Healthcare ConferenceDecember 4, 202510:50 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-

    12/2/25 7:09:32 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

    Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in patients receiving only cyclophosphamideEnrollment streamlined across Ntrust-1 and Ntrust-2 under a combined independent Data Safety Monitoring Board (iDSMB) to guide dose escalation Initial data for NKX019 in multiple autoimmune indications expected to be presented at a medical conference in 2026Cash balance of $316.5 million on September 30, 2025, including cash, cash equivalents, and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Ca

    11/10/25 4:01:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta to Participate in November Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month: Stifel 2025 Healthcare ConferenceNovember 12, 202510:40 a.m. ET – fireside chat TD Cowen's Immunology & Inflammation SummitNovember 13, 20255 p.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company a

    10/30/25 1:14:55 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ra Capital Management, L.P. bought $30,000,000 worth of shares (3,000,000 units at $10.00) (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    3/29/24 5:38:04 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    George Simeon bought $20,000,000 worth of shares (2,000,000 units at $10.00) (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    3/28/24 4:30:06 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nkarta Inc.

    SC 13G - Nkarta, Inc. (0001787400) (Subject)

    12/13/24 5:02:47 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

    SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

    11/14/24 4:05:12 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

    SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

    11/14/24 8:55:31 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Leadership Updates

    Live Leadership Updates

    View All

    Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

    SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space. Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought

    6/6/25 8:52:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

    Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $351.9 million on March 31, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 14, 2025

    5/14/25 4:01:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

    SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings. "This new leadership structure enables Nkarta to meet this transformative moment for cell therapy as

    7/16/24 6:01:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Financials

    Live finance-specific insights

    View All

    Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

    New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile Off-the-shelf accessibility and proprietary engineering could eliminate burdens of autologous products and may enable differentiating conditioning regimen Resource prioritization and cost reductions expected to extend cash runway by one year into 2026 to support important clinical data readouts in 2024 Estimated cash and cash equivalents of $278.4 mil

    10/17/23 7:01:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

    SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m. ET to discuss clinical program updates and organizational cost measures and resource prioritization to support clinical milestones. Conference Call and WebcastTo access the conference call, please register through this link: https://nkarta-business-update.open-exchange.net/registration A replay will be archived on the Investors section of Nkarta's website, www.nkartatx.com, for approximately four weeks. About NkartaNkart

    10/16/23 4:01:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

    Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine)In patients with r/r AML treated with a three-dose regimen of NKX101 at 1.5 billion cells per dose after fludarabine/Ara-C for lymphodepletion, n=6 4 of 6 patients achieved complete response (67% CR/CRi, 50% CR rate)2 CRs with MRD negativity1 patient deepened response to MRD negative CRi with additional cycles NKX101 was well tolerated across dose-levels and lymphodepletion regimensExpansion cohort incorporating Ara-C based lymphodepletion expected to be the basis of NKX101 development moving forwardUpdated clinic

    6/27/23 7:01:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care